DOCSLIB.ORG

Printer-Friendly

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Printer-Friendly Regulations of Connecticut State Agencies Sec. 21a-243-9. Controlled substances in schedule III The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in Schedule III: (a) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Benzphetamine; (2) Chlorphentermine; (3) Clortermine; (4) Phendimetrazine. (b) Unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system: (1) Any compound, mixture or preparation containing: Amobarbital, Secobarbital, Pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule; (2) Any suppository dosage form containing Amobarbital, Secobarbital, Pentobarbital or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository; (3) Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules, except that the following analgesic products shall not be considered to be controlled substances: (A) Products containing a ratio of fifteen milligrams of long or intermediate acting barbiturates combined with at least one of the following: (i) 188 mg aspirin; (ii) 375 mg salicylamide; or (iii) 70 mg phenacetin, acetanilid or acetaminophen; (B) Products containing a ratio of fifteen milligrams of short acting barbiturates combined with at least one of the following: (i) 307 mg aspirin; (ii) 614 mg salicylamide; or (iii) 106 mg phenacetin, acetanilid or acetaminophen; (4) Any compound, mixture or preparation containing equal weights of both tiletamine and zolazepam or any salt thereof and not mixed with other psychoactive substances; (5) Chlorhexadol; (6) Embutramide; (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product; (8) Ketamine or any salt thereof; (9) Lysergic acid; (10) Lysergic acid amide; - 1- Regulations of Connecticut State Agencies (11) Methyprylon; (12) Sulfondiethylmethane; (13) Sulfonethylmethane; (14) Sulfonmethane. (c) Buprenorphine. (d) Nalorphine. (e) Any material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof: (1) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium; (2) not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (3) not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; (4) not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (5) not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit,with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (6) not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts; (7) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (8) not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. (f) Unless expressly intended for administration through implants to nonhuman species and approved for such use by the Federal Food and Drug Administration, any anabolic steroid including but not limited to, any of the following, or any isomer, ester, salt or derivative of the following that acts in the same manner on the human body: (1) 3[beta],17-dihydroxy-5a-androstane; (2) 3[alpha],17[beta]-dihydroxy-5a-androstane; (3) 5[alpha]-androstan-3,17-dione; (4) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene); (5) 1-androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene); (6) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene); (7) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene); (8) 1-androstenedione ([5[alpha]]-androst-1-en-3,17-dione); - 2- Regulations of Connecticut State Agencies (9) 4-androstenedione (androst-4-en-3,17-dione); (10) 5-androstenedione (androst-5-en-3,17-dione; (11) Boldenone; (12) Boldione; (13) Chlorotestosterone; (14) Clostebol; (15) Dehydrochlormethyltestosterone; (16) [Delta]1-dihydrotestosterone (a.k.a. ‘1-testosterone’) (17[beta]- hydroxy-5[alpha]- androst-1-en-3-one); (17) desoxymethltestosterone; (18) Dihydrotesterone; (19) Drostanolone; (20) Ethylestrenol; (21) Fluoxymesterone; (22) Formebulone; (23) Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]- furazan); (24) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one; (25) 4-hydroxytestosterone (4,17[beta]-dihydroxy-androst-4-en-3-one); (26) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3- one); (27) Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5-androstan-3- one); (28) Mesterolone; (29) Methandienone; (30) Methandranone; (31) Methandriol; (32) Methandrostenolone; (33) Methenolone; (34) 17[alpha]-methyl-3[beta], 17[beta]-dihydroxy-5a-androstane; (35) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5a-androstane; (36) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene; (37) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]- hydroxyestr-4-en-3-one); (38) Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one); (39) Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one); (40) Methyltesterone; (41) Mibolerone; (42) 17[alpha]-methyl-[Delta]1-dihydrotestosterone (17b[beta]- hydroxy-17[alpha]- methyl-5[alpha]-androst-1-en-3-one) (a.k.a. ‘17- [alpha]-methyl-1-testosterone’); (43) Nandrolone; (44) 19-nor-4,9 (10)-androstadienedione; (45) 19-nor-4-androstenediol (3[beta], 17[beta]-dihydroxyestr-4-ene); (46) 19-nor-4-androstenediol (3[alpha], 17[beta]-dihydroxyestr-4-ene); (47) 19-nor-5-androstenediol (3[beta], 17[beta]-dihydroxyestr-5-ene); (48) 19-nor-5-androstenediol (3[alpha], 17[beta]-dihydroxyestr-5-ene); (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione); - 3- Regulations of Connecticut State Agencies (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione; (51) Norbolethone (13[beta], 17[alpha]-diethyl-17[beta]-hydroxygon- 4-en-3-one); (52) Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one); (53) Norethandrolone; (54) Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3- one); (55) Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one); (56) Oxandrolone; (57) Oxymesterone; (58) Oxymetholone; (59) Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3- one); (60) Stanolone; (61) Stanozolol; (62) Testolactone; (63) Testosterone; (64) Tetrahydrogestrinone (13[beta], 17[alpha]-diethyl-17[beta]- hydroxygon-4,9,11- trien-3-one); (65) Trenbolone. (g) Chorionic gonadotropin. (h) Any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of such isomers, and esters: (1) Gamma-hydroxy butyric acid if contained in a product for which an application has been approved under section 505 of the federal food, drug and cosmetic act; or (2) Gamma-butyrolactone. (Effective November 25, 1991; Amended March 6, 2000; Amended June 10, 2003; Amended June 10, 2011) - 4-.
Load more

Recommended publications
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Precursor Ion Scanning for the Detection of New Steroid Markers
    “Precursor ion scanning for the detection of new steroid markers. Routine application for the open screening of anabolic steroids and evaluation of population factors in the detectability of these markers” P. Mendoza, F. Delbeke, K. Deventer, P. Meuleman, J. Segura, R. Ventura (Fondacio IMIM, Barcelona, Spain) K. Deventer, P. Van Eenoo, O. Pozo Mendoza (Ghent University, Belgium) PROJECT REVIEW This project aims at four goals: A. Interpretation and evaluation of precursor ion scanning chromatograms (urine profile recognition) In the field of anti-doping control, chromatograms from target steroid-analysis are generally evaluated and interpreted visually by the analyst which is trained for this purpose. A similar approach will be adopted for evaluating the precursor scanning chromatograms. To get acquainted with the chromatograms, around 50 blank samples will be analysed. In a second step precursor ion scan chromatograms obtained from controlled administration studies (e.g. methyltestosterone, methanedienone,…) and from adverse analytical findings from routine target screening will also be investigated to get acquainted with positive samples. The applicability of instrument software for this purpose will be evaluated. B. Application to real samples Urine-samples will be analysed. These samples will include all out of competition samples and both out of competition samples and in competition samples C. Study of the influence of different population factors in the detectability of different markers for several anabolic steroids A single dose of the previously studied steroids (stanozolol and methyltestosterone) will be administered to six volunteers belonging to different population groups. Urine will be collected for three weeks and a method including all feasible markers will be applied.
    [Show full text]
  • Controlled Substances Included; Rules. Sec. 7216
    PUBLIC HEALTH CODE (EXCERPT) Act 368 of 1978 333.7216 Schedule 3; controlled substances included; rules. Sec. 7216. (1) The following controlled substances are included in schedule 3: (a) Unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system, including their salts, isomers, including optical, position, or geometric isomers, and salts of the isomers if the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: Benzphetamine Mediatric tabs Chlorphentermine Mediatric liquid Clortermine Phendimetrazine Edrisal tabs Special formula 711 tabs Genegesic caps Thora Dex No. 1 tab Hovizyme tabs Thora Dex No. 2 tab Mazindol (b) Unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system, including their salts, isomers, including optical, position, or geometric isomers, and salts of the isomers if the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: Chlorhexadol Phencyclidine Glutethimide Sulfondiethylmethane Lysergic acid Sulfonethylmethane Lysergix acid amide Sulfonmethane Methyprylon (c) Nalorphine. (d) Any substance that contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances that are specifically listed in other schedules. (e) A compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or a salt of amobarbital, secobarbital, or pentobarbital, and 1 or more other active medicinal ingredients that are not listed in a schedule.
    [Show full text]
  • ARTICLE 33: NEW YORK STATE CONTROLLED SUBSTANCES ACT As of January 26, 2017 +
    ARTICLE 33: NEW YORK STATE CONTROLLED SUBSTANCES ACT As of January 26, 2017 + Notice The information contained in this document is not the official version of the New York State Public Health Law. No representation is made as to its accuracy. To ensure accuracy and for evidentiary purposes, reference should be made to the official version available on the New York State Legislature Web site. Click on the link for "Laws of New York" and then the link for "PBH Public Health". Page TITLE 1 – GENERAL PROVISIONS 3300 - Short Title 4 3300a- Legislative purposes 4 3301 - Applicability of this article to actions and matters occurring or arising before and after the effective date. 4 3302 - Definitions of terms of general use in this article 4 3304 - Prohibited acts 7 3304* - Prohibited acts 8 3305 - Exemptions 8 3306 - Schedules of controlled substances 9 3307 - Exception from schedules 23 3308 - Powers and duties of the commissioner 24 3309 - Opioid overdose prevention 24 3309a - Prescription pain medication awareness program 26 TITLE 2 – MANUFACTURE AND DISTRIBUTION OF CONTROLLED SUBSTANCES 3310 - Licenses for manufacture or distribution of controlled substances 28 3311 - Authority to issue initial licenses, amended licenses and to renew licenses 29 3312 - Application for initial license 29 3313 - Granting of initial license 29 3315 - Applications for renewal of licenses to manufacture or distribute controlled substances 30 3316 - Granting of renewal of licenses 30 3318 - Identification of controlled substances 31 3319 - Distribution of free
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • International Classification of Diseases
    INTERNATIONAL CLASSIFICATION OF DISEASES MANUAL OF THE INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES, INJURIES, AND CAUSES OF DEATH Based on the Recommendations of the Eighth Revision Conference, 1965, and Adopted by the Nineteenth World Health Assembly Volume 2 ALPHABETICAL INDEX WORLD HEALTH ORGANIZATION GENEVA 1969 Volume 1 Introduction List of Three-digit Categories Tabular List of Inclusions and Four-digit Sub- categories Medical Certification and Rules for Classification Special Lists for Tabulation Definitions and Recommendations Regulations Volume 2 Alphabetical Index PRINTED IN ENGLAND CONTENTS Introduction Page General arrangement of the Index ....................................... VIII Main sections ............................................................... VIII Structure ..................................................................... IX Code numbzrs .............................................................. x Primary and secondary conditions. ................................... x Multiple diagnoses. ........................................................ XI Spelling....................................................................... XI Order of listing ............................................................. Conventions used in the Index ........................................... XII Parentheses. ................................................................. XII Cross-referexes ........................................................... XI1 Abbreviation NEC. ......................................................
    [Show full text]
  • Chapter 329 [New] Uniform Controlled Substances Act
    CHAPTER 329 [NEW] UNIFORM CONTROLLED SUBSTANCES ACT Part I. General Provisions Section 329-1 Definitions 329-2 Hawaii advisory commission on drug abuse and controlled substances; number; appointment 329-3 Annual report 329-4 Duties of the commission Part II. Standards and Schedules 329-11 Authority to schedule controlled substances 329-12 Nomenclature 329-13 Schedule I tests 329-14 Schedule I 329-15 Schedule II tests 329-16 Schedule II 329-17 Schedule III Tests 329-18 Schedule III 329-19 Schedule IV tests 329-20 Schedule IV 329-21 Schedule V tests 329-22 Schedule V 329-23 Republishing and distribution of schedules Part III. Regulation of Manufacture, Distribution, Prescription, and Dispensing of Controlled Substances 329-31 Rules 329-31.5 Clinics 329-32 Registration requirements 329-33 Registration 329-34 Revocation and suspension of registration 329-35 Order to show cause 329-36 Records of registrants 329-37 Filing requirements 329-38 Prescriptions 329-39 Labels 329-40 Methadone treatment programs Part IV. Offenses and Penalties 329-41 Prohibited acts B-penalties 329-42 Prohibited acts C-penalties 329-43 Penalties under other laws 329-43.5 Prohibited acts related to drug paraphernalia Amended 0612 1 329-44 Notice of conviction to be sent to licensing board, department of commerce and consumer affairs 329-45 Repealed 329-46 Prohibited acts related to visits to more than one practitioner to obtain controlled substance prescriptions 329-49 Administrative penalties 329-50 Injunctive relief Part V. Enforcement and Administrative Provisions 329-51 Powers of enforcement personnel 329-52 Administrative inspections 329-53 Injunctions 329-54 Cooperative arrangements and confidentiality 329-55 Forfeitures 329-56 Burden of proof; liabilities 329-57 Judicial review 329-58 Education and research 329-59 Controlled substance registration revolving fund; established Part VI.
    [Show full text]
  • House Bill No.11 (2019)
    LEGISLATURE OF THE STATE OF IDAHO Sixty-fifth Legislature First Regular Session - 2019 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. 11 BY HEALTH AND WELFARE COMMITTEE 1 AN ACT 2 RELATING TO CONTROLLED SUBSTANCES; AMENDING SECTION 37-2705, IDAHO CODE, TO 3 REVISE THE LIST OF SCHEDULE I CONTROLLED SUBSTANCES; AMENDING SECTION 4 37-2709, IDAHO CODE, TO PROVIDE AN EXCLUSION AND TO MAKE A TECHNICAL 5 CORRECTION; AMENDING SECTION 37-2713, IDAHO CODE, TO REVISE THE LIST OF 6 SCHEDULE V DRUGS AND SUBSTANCES; AND DECLARING AN EMERGENCY. 7 Be It Enacted by the Legislature of the State of Idaho: 8 SECTION 1. That Section 37-2705, Idaho Code, be, and the same is hereby 9 amended to read as follows: 10 37-2705. SCHEDULE I. (a) The controlled substances listed in this sec- 11 tion are included in schedule I. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters, and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-pip- 17 eridinyl]-N-phenylacetamide); 18 (2) Acetylmethadol; 19 (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylac- 20 etamide); 21 (4) Allylprodine; 22 (5) Alphacetylmethadol (except levo-alphacetylmethadol also known as 23 levo-alpha-acetylmethadol, levomethadyl acetate or LAAM); 24 (6) Alphameprodine; 25 (7) Alphamethadol; 26 (8) Alpha-methylfentanyl; 27 (9) Alpha-methylthiofentanyl
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Schedules of Controlled Substances (.Pdf)
    PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS. This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of Health, and will take effect 21 days following publication of this notice in the Texas Register. Changes to the schedules are designated by an asterisk (*). Additional information can be obtained by contacting the Department of State Health Services, Drugs and Medical Devices Unit, P.O. Box 149347, Austin, Texas 78714-9347. The telephone number is (512) 834-6755 and the website address is http://www.dshs.texas.gov/dmd. SCHEDULES Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated. SCHEDULE I Schedule I consists of: -Schedule I opiates The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation: (1) Acetyl-α-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (Other name:
    [Show full text]
  • 6-Oxo) and Metabolites
    WADA Technical Letter – TL21 Document Number: TL21 Version Number: 2.0 Written by: WADA Science Approved by: WADA Executive Committee Reviewed by: WADA Laboratory Expert Group Date: 21 December 2020 Effective Date: 1 January 2021 IN SITU FORMATION OF 4-ANDROSTENE-3,6,17-TRIONE (6-OXO) AND METABOLITES 1.0 Introduction WADA wishes to draw the attention of the Laboratories to the possible detection of 6-Oxo- androstenedione (6-oxo) and Metabolites in urine Samples resulting from the in situ transformation of DHEA. It has been observed that microbial contamination may induce modifications in the structure of some endogenous steroids (e.g., DHEA) by oxidoreductive and other reactions, leading to the formation of hydroxylated and oxidized derivatives, which may hamper the interpretation of results (Figure 1) [1,2]. In additon, some steroids which are normally excreted as glucuronide conjugates [e.g. 6α-hydroxy Metabolites of 6-oxo such as 6α-hydroxyandrostenedione (6α-OH-AD) and 6α-hydroxytestosterone (6α-OH-T)] might be detected as aglycons because of bacteria-mediated hydrolysis [3,4]. Figure 1 illustrates the possibility of in situ biotransformation of endogenous DHEA into the prohibited aromatase inhibitor 6-oxo, which would be detected in a urine Sample without its major Metabolite 6α-OH-AD [2,5]. Figure 1. DHEA oxidation followed by isomerization of the double bond, formation of androst-4-ene-3,17-dione (AD), boldione and the respective 6β-OH-derivatives. The oxidation of the hydroxyl group at the C6-β position leads to the formation of 4-androstene-3,6,17-trione (6-oxo) [2,5].
    [Show full text]